United Kingdom Musculoskeletal Disorders Treatment Drugs Market to be dominated by Oral Segment through 2028
Government initiatives and growing
advancements in technology to drive the United Kingdom
Musculoskeletal Disorders Treatment Drugs Market.
According to TechSci Research report, “United
Kingdom Musculoskeletal Disorders Treatment Drugs Market – By Region, Competition
Forecast & Opportunities, 2018-2028,” the United Kingdom Musculoskeletal Disorders Treatment
Drugs Market is anticipated to register a high CAGR during the forecast period.
This can be ascribed to the increase in technological advancements associated
with the production of musculoskeletal disorders treatment drugs.
Growing advancements in technology associated
with drug discovery, diagnostic techniques, and biologic therapies for the
management of musculoskeletal disorders are some of the significant factors
that are leading to the growth of the United Kingdom Musculoskeletal Disorders
Treatment Drugs Market in the forecast period. State-of-the-art imaging
techniques such as computed tomography (CT), magnetic resonance imaging (MRI),
and ultrasound have enabled healthcare professionals to obtain detailed images
of musculoskeletal structures, aiding efficiently in the treatment of
arthritis, osteoporosis, and spinal disorders. Moreover, the growing existence
of drug delivery methods such as intra-articular injections, implantable drug
delivery systems, hydrogels, scaffolds, gene therapy, and others has regulated
the demand for musculoskeletal disorders treatment drugs in recent years.
Steroids, hyaluronic acid, platelet-rich plasma (PRP), and mesenchymal stem
cells are some of the preventive substances for osteoarthritis that are
delivered by intra-articular injections.
Furthermore, growing mergers and acquisitions
between leading pharmaceutical companies with an approach to combine their
expertise for producing novel drugs are also expected to propel the growth of
the United Kingdom Musculoskeletal Disorders Treatment Drugs Market in the
upcoming years. For instance, GlaxoSmithKline plc. has acquired Pfizer's
consumer healthcare business in a joint venture deal worth approximately USD12.7
billion. This acquisition has enabled GlaxoSmithKline plc. to strengthen its
position in the consumer healthcare market. Moreover, AstraZeneca Plc. has
acquired Alexion Pharmaceuticals, a biopharmaceutical company that specializes
in treating rare diseases, for USD39 billion. The acquisition enabled
AstraZeneca Plc. to expand its presence in the rare disease market.
The growing concern of the government towards
the increase in the prevalence of musculoskeletal disorders is one of the vital
factors expected to boost the growth of the United Kingdom Musculoskeletal
Disorders Treatment Drugs Market in the forecast period. Public Health England
(PHE) launched the Musculoskeletal (MSK) Health Improvement program in April
2018. The framework identifies a shared vision supported by goals,
deliverables, and desired outcomes, providing a strategic overview for the
prevention of musculoskeletal disorders in England. Moreover, the Fit for Work
initiative has been introduced to support employees with health conditions,
including musculoskeletal disorders. It provides free expert advice to
employers, employees, and general practitioners, assisting them in managing
their health conditions and facilitating their return to the workplace.
The United Kingdom has a publicly funded
healthcare system known as the National Health Service (NHS), which provides
healthcare services to the population. Healthcare expenditure in the UK is
primarily financed through taxation and government funding. The developing
economy of the country and the abrupt rise in healthcare expenditure in the
United Kingdom are driving the growth of the United Kingdom Musculoskeletal
Disorders Treatment Drugs Market at an enormous pace in the forecast period. In
2021, musculoskeletal disorders accounted for 28% of all work-related ill
health in Britain, leading to an expenditure of approximately USD16.8 billion
in Britain for the treatment of these disorders.
However, the expensive costs of premium
drugs, the development of alternative therapies for the prevention of
musculoskeletal disorders, and stringent regulatory requirements are expected
to slow down the growth of the market in the coming years.
Browse over XX market data Figures and spread through 85 Pages
and an in-depth TOC on "United Kingdom Musculoskeletal Disorders Treatment Drugs Market”
The United Kingdom Musculoskeletal Disorders Treatment Drugs market segmentation
is based on Drug Type, Route of Administration, Distribution Channel, Drug
Classification, By Company, and Region.
Based on Route of
Administration, the market is further divided into Parenteral and Oral. Oral
segment is likely to dominate the market in the forecast period. This can be ascribed to high
preference of patients for oral medications due to convenience of
administration and their affordable cost over other forms of treatment.
Some of the major companies operating in the United Kingdom Musculoskeletal Disorders Treatment Drugs Market include:
- GlaxoSmithKline plc.
- AstraZeneca PLC.
- Novartis
Pharmaceuticals UK Ltd.
- Bayer plc.
- Johnson &
Johnson Pvt. Ltd.
- Reckitt Benckiser
Group PLC.
- F. Hoffmann-La
Roche Ltd.
- Marksans Pharma
Ltd.
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“Midwest
region is expected to dominate the musculoskeletal disorders treatment drugs
market in United Kingdom. The presence of leading pharmaceutical companies in
the market, that are coming up with novel treatment strategies every year for
the prevention of different musculoskeletal disorders, is expected to register
impressive growth for the United Kingdom Musculoskeletal Disorders Treatment
Drugs Market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based global management consulting
firm.
“United Kingdom
Musculoskeletal Disorders Treatment Drugs Market By Drug Type (Analgesics, DMARDS,
Corticosteroids, Others), By Route of Administration (Oral, Parenteral), By Distribution
Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail
Pharmacies), By Drug Classification (Branded Drugs, Generic Drugs), By Region,
Competition Forecast & Opportunities, 2018-2028F,” has evaluated the future growth potential of
United Kingdom Musculoskeletal Disorders Treatment Drugs Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in United Kingdom Musculoskeletal Disorders
Treatment Drugs Market.
Contact
Mr. Ken
Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
https://www.techsciresearch.com